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INTRODUCTION 
I
n the last issue of the Archive of Oncology I wrote about importance of our immune sys-
tem against ovarian cancer. Maybe such a thoughts were only illusions in the past, but
nowadays many laboratories worldwide examine the possibilities of our own immune sys-
tem to recognize tumor cell and become active against it. Recently, another paper about a
tumor infiltrating lymphocytes and their importance as a prognostic factor in endometrial
cancer has been published in the Clinical Cancer Research. I would like to present this arti-
cle as another important news in this field of immuno-oncology.
In developed countries, adenocarcinoma of the endometrium is the most common gyne-
cological cancer; however, in developing countries, it is much less frequent than carcino-
ma of the cervix. It accounts for only 2% of all cancer-related deaths; the number of women
dying of this disease is still significant (1). The median age of patients at the diagnosis of
endometrial carcinoma is 63 years (2). The incidence of endometrial carcinoma is highly
dependent on age; there are 12 cases per 100,000 women at 40 years of age and 84 per
100,000 at 60 (3). Seventy-five percent of women with endometrial carcinoma are post-
menopausal (4). Ninety-seven percent of all cancers of the uterus arise from the glands of
the endometrium and are known as endometrial carcinomas. Endometriod adenocarcinoma
is the most frequent histopathologic subtype.
Christopherson et al. described adenocarcinoma, adenoacanthoma, adenosquamous car-
cinoma, clear-cell carcinoma, and papillary serous carcinoma, which occurred in 60%,
22%, 7%, 6%, and 5% of the cases, and found five-year survival rates of 80%, 88%, 53%,
44%, and 68%, respectively, for stage I disease (5,6).
Multiple prognostic factors exist for endometrial cancer. These prognostic factors are: 
* Stage of the disease
* Histopathological type of tumor, 
* The degree of histological differentiation,
* Myometrial invasion,
* Peritoneal cytology,
* Lymph node metastasis 
Where is the place of the immune system in this story about prognostic factors?
The functioning of the antigen-specific immune system is based on a division of labor
between T cells and antibody-producing B cells (7). Tumor-infiltrating lymphocytes (TILs)
are one of the major immune components infiltrating solid tumors. The majority of TILs in
endometrial carcinomas express the CD8+suppressor/ cytotoxic phenotype, and minor
subsets express B-lymphocyte and macrophage markers (8,9).  Natural killer cells are vir-
tually absent in endometrial tumors (9). Svetlana Kondratiev et al. investigated intratumoral
CD8+T lymphocytes as a prognostic factor of survival in endometrial carcinoma (10).
They examined paraffin blocks containing tissue samples that had been obtained from 90
patients with endometrial carcinoma between the years 1991 and 1999 and were retrieved
from the archives of the Carmel Medical Center. All tissues had been obtained by hysterec-
tomy. None of the patients had undergone radiation or chemotherapy before surgery. 
According to results of Kondratiev et al. the relationship between the number of CD8+ lym-
phocytes and other clinicopathological variables was assessed by univariate analysis.
Tumor grade and stage were not significantly associated with the number of CD8+ lym-
phocytes present in the compartments evaluated. The four compartments were evaluated:
intraepithelial lymphocytes within superficial tumor epithelium, within the tumor epithelium
at the invasive border, within the underlying stroma, and in the perivascular areas of the
myometrium (Figure 1).
Table 1. Clinicopathological characteristics of the patients with endometrial carcinoma
(Taken from ref. 10)The number of CD8+ lymphocytes in the underlying tumor stroma significantly correlated
with the presence of vascular invasion. The number of perivascular CD8+ lymphocytes
was significantly associated with vascular invasion.  Tumors with >20 perivascular CD8+
lymphocytes showed an increased risk for vascular invasion. Also they found by univariate
analysis stage, grade, and vascular invasion all correlated significantly with patient survival
in the endometrioid carcinoma group (stage, P< 0.0054 for I versus II; grade, P< 0.042
for I versus II and 0.022 for I versus III; vascular invasion, P< 0.0001).
A significant correlation between the number of intraepithelial CD8+T lymphocytes at the
invasive border and patient outcome in the endometrioid carcinoma group was found
(Figure 2). Greater overall survival was seen in patients with tumors exhibiting >10 intraep-
ithelial lymphocytes/field (x 200) at the invasive border (P = 0.027). At the end of the
study, 87% of the patients with >10 lymphocytes/field were alive compared with 50% of
patients with <10 lymphocytes/field. The number of lymphocytes present within the under-
lying stroma and in the superficial tumor epithelium did not show a significant correlation
with prognosis. The number of perivascular lymphocytes (total number or CD8+subsets)
also did not correlate with survival.
Kondratiev et al. demonstrated for the first time that infiltration of CD8+T cells in the tumor
epithelium at the invasive border is a favorable prognostic factor in endometrial carcinoma
patients. The mechanism of TIL activation and distribution of activated TILs in endometrial
carcinoma is not clear. Lymphocyte activation and proliferation may occur after presenta-
tion of a tumor-specific antigen by professional antigen-presenting cells or by tumor cells
themselves in a HLA-restricted fashion (11).
Ferguson et al. reported that MHC class I antigens were detected in four of eight endome-
trial carcinomas compared with their normal tissue counterparts (9). Failure to express
MHC class I antigens by malignant cells arises from their ability to transform and be select-
ed during tumor progression and is thought to be an advantage of tumor resistance to
attack by cytotoxic T cells (9). Interestingly, some endometrial carcinomas express MHC
class II DR antigen on the epithelial cells, suggesting that other antitumor mechanisms also
play a role in the immune response (9). Alternatively, the CTLs in endometrial carcinoma
may be nonspecifically activated by a mechanism of a general inflammatory reaction, such
as the release of activating cytokines (12).
In conclusion, Kondratiev’s results indicate that increased numbers of TILs at the invasive
border of endometrial carcinomas may be a reliable independent prognostic factor of
improved patient survival. TILs in endometrial carcinoma express immunohistochemical
markers of cytotoxic activity, suggesting that CTL-mediated cytotoxicity may be a key
mechanism active in host versus tumor immune response.
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Figure 1. Immunohistochemistry for cytotoxic markers. Distribution of CD8+lymphocytes
in superficial tumor epithelium (A), tumor epithelium at the invasive border (B; upper) and
underlying stroma (B; lower), and perivascular areas in the myometrium (C)(Taken from
ref. 10)
Figure 2. Kaplan-Meier survival curves for endometrioid endometrial carcinoma patients,
with 10 CD8+ lymphocytes/computerized x200 field used as the cutoff point ( Taken from
ref. 10)